content: <PAGE>
                    SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date  of  Report  (Date of earliest event reported)       JULY 17, 1996 
  
                               ENZON, INC.
  
          (Exact  name  of  registrant  as  specified  in its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  
  
  
  <PAGE>
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc.  ("Enzon"  or the "Company") announced that  it  has
  received  three  additional  United States  patents  for  its  Single-Chain
  Antigen-Binding (SCA(R)) protein  technology, which is one of the Company's
  proprietary core technologies.
  
            SCA proteins, like monoclonal  antibodies,  (MAbs),  are  used to
  deliver  therapeutic  agents  to  target  disease sites in the body.  Enzon
  believes SCA proteins offer significant advantages  over  conventional MAbs
  such  as  greater  tumor  penetration for cancer imaging and therapy,  more
  specific localization to targeted  disease  sites  in  the  body, decreased
  immunogenic  reactions,  and  easier,  more  cost  effective  manufacturing
  processes.   In  addition  to  these  advantages, because SCA proteins  are
  developed at the gene level, they are better  suited  for targeted delivery
  of  gene  therapy  vectors  and  fully-human SCA proteins can  be  isolated
  directly, with no need for costly  "humanization"  procedures.   Also, many
  gene  therapy  methods  require  that  proteins  be produced in active form
  inside   cells.   SCA  proteins  can  be  produced  through   intracellular
  expression (inside cells) more readily than MAbs.
  
            The  SCA  patents  issued were U.S. Patent No. 5,534,621 covering
  immunopurification methods, U.S.  Patent No. 5,518,889 covering immunoassay
  methods and U.S. Patent No. 5,455,030 covering immunotherapeutic methods.
  
            Enzon has licensed the SCA protein technology primarily on a non-
  exclusive basis to more than a dozen  companies  including  several  global
  pharmaceutical  companies  such  as  Baxter Healthcare, Eli Lilly, Bristol-
  Myers Squibb, and the Gencell division of Rhone-Poulenc Rorer.  Under these
  licenses, the Company has received approximately  $6  million  in  up front
  payments and is entitled to receive additional payments upon achievement of
  specified  development  milestones  and  royalties  on  sales of any future
  products developed that utilize Enzon's SCA technology.
  
            Clinical  trials for seven products using SCA protein  technology
  have been started by  licensees  as well as academic institutions.  Some of
  the areas being explored are cancer therapy, cardiovascular indications and
  AIDS.
  <PAGE>
  
  
  
                              SIGNATURES
  
  
       Pursuant to the requirements  of  the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  July 22, 1996
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 3942}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96597367"}, "business-address": {"street1": "20 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date  of  Report  (Date of earliest event reported)       JULY 17, 1996 
  
                               ENZON, INC.
  
          (Exact  name  of  registrant  as  specified  in its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  ITEM 5.  OTHER EVENTS
  
            Enzon,  Inc.  ("Enzon"  or the "Company") announced that  it  has
  received  three  additional  United States  patents  for  its  Single-Chain
  Antigen-Binding (SCA(R)) protein  technology, which is one of the Company's
  proprietary core technologies.
  
            SCA proteins, like monoclonal  antibodies,  (MAbs),  are  used to
  deliver  therapeutic  agents  to  target  disease sites in the body.  Enzon
  believes SCA proteins offer significant advantages  over  conventional MAbs
  such  as  greater  tumor  penetration for cancer imaging and therapy,  more
  specific localization to targeted  disease  sites  in  the  body, decreased
  immunogenic  reactions,  and  easier,  more  cost  effective  manufacturing
  processes.   In  addition  to  these  advantages, because SCA proteins  are
  developed at the gene level, they are better  suited  for targeted delivery
  of  gene  therapy  vectors  and  fully-human SCA proteins can  be  isolated
  directly, with no need for costly  "humanization"  procedures.   Also, many
  gene  therapy  methods  require  that  proteins  be produced in active form
  inside   cells.   SCA  proteins  can  be  produced  through   intracellular
  expression (inside cells) more readily than MAbs.
  
            The  SCA  patents  issued were U.S. Patent No. 5,534,621 covering
  immunopurification methods, U.S.  Patent No. 5,518,889 covering immunoassay
  methods and U.S. Patent No. 5,455,030 covering immunotherapeutic methods.
  
            Enzon has licensed the SCA protein technology primarily on a non-
  exclusive basis to more than a dozen  companies  including  several  global
  pharmaceutical  companies  such  as  Baxter Healthcare, Eli Lilly, Bristol-
  Myers Squibb, and the Gencell division of Rhone-Poulenc Rorer.  Under these
  licenses, the Company has received approximately  $6  million  in  up front
  payments and is entitled to receive additional payments upon achievement of
  specified  development  milestones  and  royalties  on  sales of any future
  products developed that utilize Enzon's SCA technology.
  
            Clinical  trials for seven products using SCA protein  technology
  have been started by  licensees  as well as academic institutions.  Some of
  the areas being explored are cancer therapy, cardiovascular indications and
  AIDS.
  SIGNATURES
  
       Pursuant to the requirements  of  the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  July 22, 1996
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /s/KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial
                                           Officer